


Product Name : Vodobatinib
Cat. No. : PC-38379
CAS No. : 1388803-90-4
Molecular Formula : C₂₇H₂₀ClN₃O₂
Molecular Weight : 453.926
Target : Bcr-Abl
Solubility : 10 mM in DMSO



Biological Activity

Vodobatinib (K0706) is a potent, selective inhibitor of **BCR-ABL1** with IC₅₀ of 7 nM (wt BCR-ABL1), exhibits activity against most clinically important BCR-ABL1 point mutants (M244V, IC₅₀=22 nM).

The only BCR-ABL1 point mutants with IC₅₀ above 100 nM are: BCR-ABL1L248R (IC₅₀: 167 nM), BCR-ABL1Y253H (IC₅₀: 154 nM), BCR-ABL1E255V (IC₅₀: 165 nM) and BCR-ABL1T315I (IC₅₀: 1967 nM).

Vodobatinib (K0706) demonstrated direct, potent inhibition of BCR-ABL1 tyrosine autophosphorylation as well as inhibition of BCR-ABL1L248R, BCR-ABL1Y253H and BCR-ABL1E255V at high concentrations in a panel of cell lines expressing TKI resistant mutants of BCR-ABL1.

Vodobatinib (K0706) does not inhibit mutant BCR-ABL1T315I.

Vodobatinib (K0706) exhibited pre-clinical activity in Philadelphia chromosome-positive leukemia.

References

Antelope O, et al. *Exp Hematol*. 2019 Sep;77:36-40.e2.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com